Course and long-term treatment of schizophrenic psychoses

Pharmacopsychiatry

Volumn 37, Issue SUPPL. 2, 2004, Pages

  Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

AFFECTIVE PSYCHOSIS; CLINICAL RESEARCH; CLINICAL TRIAL; CONCEPT FORMATION; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; DRUG DOSE REGIMEN; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HALLUCINATION; HUMAN; LONG TERM CARE; MANIA; MENTAL DISEASE; META ANALYSIS; NEGATIVE SYNDROME; OUTCOMES RESEARCH; PARANOID PSYCHOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

AFFECTIVE DISORDERS, PSYCHOTIC; AGE FACTORS; CLINICAL TRIALS; EARLY DIAGNOSIS; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MODELS, BIOLOGICAL; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 9644294583     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832666     Document Type: Conference Paper

References (67)

1. Arato M, O'Connor R, Meltzer H. Zeus study group. Ziprasidone in the long-term treatment of negative symptoms and the prevention of exacerbation of schizophrenia. Int Clin Psychopharmacol 2002; 17: 207-215
2. Bäuml J, Kissling W, Meurer C, Wais A, Lauter H. Informationszentrierte Angehörigengruppe zur Complianceverbesserung bei schizophrenen Patienten. Psychiatr Prax 1991; 18: 48-54
3. Beasley C, Hamilton S, Dossenbach M. Relapse prevention with olanzapine. Eur Neuropsychopharmacol 2000; 10: S304
4. Bleuler M. Dementia Praecox or the group of schizophrenias. New York: International University Press, 1950
5. Bottlender R, Jager M, Groll C, Strauss A, Moller HJ. Deficit states in schizophrenia and their association with the length of illness and gender. Eur Arch Psychiatry Clin Neurosci 2001; 251: 272-278
6. Bottlender R, Sato T, Jager M, Wegener U, Wittmann J, Strauss A et al. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res 2003; 62: 37-44
7. Bottlender R, Strauß A, Möller HJ. Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. Schizophrenia Research 2000; 44: 145-150
8. Buchkremer G, Schulze-Mönking H, Holle R, Hornung WP. The impact of therapeutic relatives' groups on the course of illness of schizophrenic patients. Eur Psychiatry 1995; 10: 17-27
9. Carpenter Jr WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-583
10. Cheung HK. Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs. Br J Psychiat 1981; 138: 490-494
11. Cooper SJ, Butler A, Tweed J, Welch C, Raniwalla J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology (Berl) 2000; 150: 237-243
12. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49: 196-201
13. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
14. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998; 34: 61-69
15. Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741-773
16. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley C-MJ. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997; 48: 1571-1577
17. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32: 683-697
18. Fenton WS. Course and outcome in schizophrenia. Curr Opin Psychiatry 1997; 10: 40-44
19. Gaebel W. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment? Int Clin Psychopharmacol 1995; 9 (Supl 5): 11-16
20. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152: 379-384
21. Goldberg SC, Schooler NR, Hogarty GE, Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Arch Gen Psychiatry 1977; 34: 171-184
22. Grossman LS, Harrow M, Goldberg JF, Fichtner CG. Outcome of schizoaffective disorder at two long-term follow-ups: comparisons with outcome of schizophrenia and affective disorders. Am J Psychiatry 1991; 148: 1359-1365
23. Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J 1973; 1: 633-637
24. Hogarty GE, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. 11. Two-years relapse rates. Arch Gen Psychiatry 1974; 31: 603-608
25. Hogarty GE, Goldberg SC. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Arch Gen Psychiatry 1973; 28: 54-64
26. Jäger M, Bottlender R, Wegner U, Wittmann J, Strauss A, Möller HJ. 15-Jahres-Katamnese schizophrener Psychosen im Vergleich zu affektiven und schizoaffektiven Psychosen. In: Möller HJ, Müller N, (eds). Schizophrenie: Langzeitverlauf und Langzeittherapie Wien: Springer, 2004: 23-30
27. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990; 301: 837-842
28. Kane JM, Aguglia E, Altamura AC, Ayuso-Gutierrez JL, Brunello N, Fleischhacker WW et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8: 55-66
29. Kraepelin E. Dementia Praecox. Edinburgh: E.S. Liningstone, 1919
30. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. Br Med J 1971; 3: 599-604
31. Leucht S, Barnes T, Kissling W, Engel R, Kane JM. Relapse prevention in schizophrenia with new antipsychotics: a meta-analysis of randomized controlled trials. Am J Psychiatry 2003; 160: 1209-1222
32. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 Suppl 9: 5-9
33. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiat 1997; 170: 18-22
34. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: two years outcomes. Am J Psychiatry 2003; 160: 1405-1412
35. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry 1987; 44: 518-521
36. Marneros A, Deister A, Rohde A. Affektive, schizoaffektive und schizophrene Psychosen. Eine vergleichende Langzeitstudie. [Affective, schizoaffective and schizophrenic psychoses. A comparative long-term study]. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1991; 65: 1-454
37. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14: 515-542
38. Meltzer HY, Alphs L, Green A, Altamura AC, Anand R, Bertoli A et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91
39. Möller HJ. Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Heinrich K, (ed). Leitlinien neuroleptischer Therapie Berlin Heidelberg New York: Springer, 1990: 97-115
40. Möller HJ. Zur Vorhersage des mittelfristigen Verlaufs schizophrener Psychosen. In: Heinrich K, Klieser E, Lehmann E, (eds). Prädiktoren des Therapieverlaufs endogener Psychosen Stuttgart New York: Schattauer, 1993: 85-105
41. Möller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 2000; 1: 75-91
42. Möller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000; 1: 204-214
43. Möller HJ. Antipsychotic agents - gradually improving treatment. Br J Psychiat, 2003: In Press
44. Möller HJ. Depressive Comorbidität/Co-syndromibidität im Rahmen schizophrener Psychosen und ihre Therapie. In: Fleischhacker WW, Hummer N (eds). Schizophrene Störungen. State of the Art 3. Innsbruck: VIP Verlag, 2004: 175-202
45. Möller HJ. Der Einsatz neuer Antipsychotika in der Langzeittherapie der Schizophrenie. In: Möller HJ, Müller N, (eds). Schizophrenie. Langzeitverlauf und Langzeittherapie Vienna New York: Springer, 2004: 247-266
46. Möller HJ, Bottlender R, Groß A, Hoff P, Wittmann J, Wegner U et al. The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. Schizophr Res 2002; 56: 87-94
47. Möller HJ, Bottlender R, Wegner U, Wittmann J, Straug A. Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. Acta Psychiatr Scand 2000; 102 (Suppl 407): 54-57
48. Möller HJ, Deister A. Schizophrenie. In: Möller HJ, Laux G, Kapfhammer H-P, (eds). Psychiatrie und Psychotherapie Berlin Heidelberg New York: Springer, 2000: 997-1068
49. Möller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank J-F, Gaussares C. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 1998; 13: 99-106
50. Möller HJ, Hohe-Schramm M, Cording-Tömmel C, Schmid Bode W, Wittchen HU, Zaudig M et al. The classification of functional psychoses and its implications for prognosis. Br J Psychiatry 1989; 154: 467-472
51. Möller HJ, Kissling W, Stoll KD, Wendt G. Psychopharmakotherapie. Ein Leitfaden für Klinik und Praxis. Stuttgart: Kohlhammer, 1989
52. Möller HJ, Schmid Bode W, Cording-Tömmel C, Wittchen HU, Zaudig M, von Zerssen D. Psychopathological and social outcome in schizophrenia versus affective/schizoaffective psychoses and prediction of poor outcome in schizophrenia. Results from a 5-8 year follow-up. Acta Psychiatr Scand 1988; 77: 379-389
53. Möller HJ, von Zerssen D. Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. Berlin Heidelberg New York: Springer, 1986
54. Müller P. Die Patienten und das Ergebnis der Rezidivprophylaxe. In: Müller P, (ed). Zur Rezidivprophylaxe schizophrener Psychosen Stuttgart: Enke, 1982: 15-23
55. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000; 102: 83-86
56. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-269
57. Riedel M, Strassnig M, Möller HJ, Müller N. Die Stellung der Depot-Neuroleptika aus heutiger Sicht. In: Möller HJ, Müller N, (eds). Schizophrenia. Langzeitverlauf und Langzeittherapie Vienna New York: Springer, 2004: 215-231
58. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch Gen Psychiatry 1977; 34: 43-47
59. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000; 61: 382-386
60. Rosenheck R, Evans D, Herz L, Cramer J, Xu W, Thomas J et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in re fractory schizophrenia. Schizophr Bull 1999; 25: 709-719
61. Sheperd M. A Study of the Major Psychoses in an English Country. London: Chapman and Hall, 1957
62. Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 1997; 171: 564-568
63. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55 (Suppl B): 102-106
64. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley C-M. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998; 172: 499-505
65. Tsuang MT, Woolson RF, Fleming JA. Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch Gen Psychiatry 1979; 36: 1295-1301
66. Volz HP, Kasper S, Möller HJ, Sachs G, Höse A. Die Rolle der Kognition in der Therapie schizophrener Störungen. Wiesbaden: Deutscher Universitäts-Verlag, 2003
67. Watt DC, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 1983; 13: 663-670